Cori Clinical Raises €3.6M Seed Led by Breega to Scale AI Clinical Trial Workspace

Cori Clinical Secures €3.6M Seed Round

Cori Clinical, a London-based healthtech startup, has raised €3.6 million in Seed funding. The round was led by Breega, with participation from Enzo Ventures, HEARTFELT, Bynd VC, and Together Ventures. The funding was announced on October 7, 2026.

What Cori Clinical Does

Cori Clinical builds an AI workspace for designing and setting up clinical trials. The platform combines an organisation's internal clinical trial experience with external intelligence drawn from trial registries and regulators, including the FDA, MHRA, and EMA.

According to the company, the platform turns an initial trial brief into a full protocol, submission package, and operational plan. This positions Cori Clinical at the earliest and often most resource-intensive stage of the clinical trial lifecycle, where sponsors and CROs must translate a scientific concept into a regulator-ready design.

Traction and Customers

Cori Clinical reports that it already works with two of the world's five largest enterprise CROs. It also works with academic medical centres, including Erasmus MC in Rotterdam. These relationships suggest early validation across both commercial and academic segments of the clinical research market.

Company Background

Cori Clinical was founded in 2025 and is headquartered in London. The company operates at the intersection of healthtech and AI, applying the technology to clinical trial design and setup rather than to downstream functions such as patient recruitment or site monitoring.

The Funding

• Round type: Seed
• Amount: €3.6 million
• Currency: EUR
• Announced: October 7, 2026
• Lead investor: Breega
• Additional investors: Enzo Ventures, HEARTFELT, Bynd VC, Together Ventures

Why This Round Matters

The Seed round gives Cori Clinical capital to build on its early enterprise relationships. Clinical trial design is a document- and knowledge-heavy process, and the company's approach of pairing an organisation's internal trial experience with external regulatory and registry intelligence addresses a workflow that is typically fragmented across teams, spreadsheets, and prior submissions.

For a company founded in 2025, securing a lead investor alongside a syndicate of four additional funds signals early conviction in both the team and the market opportunity. The presence of enterprise CRO relationships at the Seed stage is notable, given that these organisations are typically cautious buyers with long evaluation cycles.

What to Watch

• How Cori Clinical converts its existing CRO and academic medical centre relationships into broader commercial deployments.
• Whether the platform expands beyond protocol and submission package generation into adjacent operational workflows.
• How the company differentiates as AI tooling for clinical development becomes a more crowded category.

Summary

Cori Clinical has raised €3.6 million in Seed funding led by Breega, with Enzo Ventures, HEARTFELT, Bynd VC, and Together Ventures participating. The London-based company, founded in 2025, provides an AI workspace that turns a clinical trial brief into a full protocol, submission package, and operational plan, drawing on internal trial experience and external intelligence from the FDA, MHRA, and EMA. It already works with two of the world's five largest enterprise CROs and with academic medical centres including Erasmus MC in Rotterdam.